Mariel Hernandez-Pérez
Daniel Enos- Department of Nephrology, Healthcare Complex Dr. Victor Rios Ruiz (CAVRR), Los Angeles, Biobio Province, Chile
Introduction: The prevalence of bone disease in peritoneal dialysis patients has been recently shown to exceed 54%, including patients with parathormone (PTH) levels within the theoretical adequate target, yet demonstrating low bone turnover on histomorphometry. Moreover, bone disease is often associated with abnormalities in calcium and phosphate metabolism, leading to tissular deposits such as extraosseous calcifications.
Case presentation: We present a 22-year-old female patient managed on peritoneal dialysis with persistent swelling of all four extremities, including the fingers, hands, and feet, accompanied by a marked decrease in PTH. Many extraosseous calcifications in the hands were seen in the X-ray images, prompting a switch from peritoneal dialysis to conventional high-flow haemodialysis and intravenous sodium thiosulphate (STS) therapy. The patient showed adequate treatment tolerance, with most calcifications disappearing after 3 months of therapy.
Conclusions: Our experience suggests that the treatment of extraosseous calcifications requires timely and multi-angle intervention. At the same time, treatment with STS has proven effective and well tolerated in this patient.
Introduction
Mineral and bone disorders (MBD) are common complications of chronic kidney disease (CKD) associated with cardiovascular outcomes and mortality in dialysis patients (1–5). The spectrum of bone disease in peritoneal dialysis patients is not yet fully understood. It has been recently shown that up to 54% of patients with parathormone (PTH) within the goal recommended by Kidney Disease Improving Global Outcomes (KDIGO) (6) exhibit low bone turnover on histomorphometry, according to Pereira et al. (7). In this case, many abnormalities of calcium and phosphate metabolism are described, mainly, the presence of positive calcium balance, which may result in PTH over-suppression (8, 9). In addition, peritoneal dialysis patients frequently have positive phosphorus balance, reflecting an ongoing intrinsic inflammatory activity, which can lead to extraosseous calcifications, especially vascular calcifications, regardless of bone turnover (10). When serum calcium is reduced, controlling phosphate and parathyroid levels is important to prevent extraosseous calcifications. Sodium thiosulphate (STS) has been used for managing metastatic calcifications, acting through three complementary mechanisms, namely, as a potent serum calcium chelator, an antioxidant, and a vasodilator agent. Herein, we report a case of a young female patient on peritoneal dialysis with adynamic bone disease (ABD) and extraosseous calcifications, successfully treated with intravenous STS as the cornerstone therapy.
Case presentation
A 22-year-old female patient with severe lupus nephritis and end-stage renal disease undergoing immunosuppressive treatment with prednisone, mycophenolate mofetil, and hydroxychloroquine, was managed on continuous ambulatory peritoneal dialysis (PD) for almost 2 years. She was receiving the following dialysis prescription: total time: 10-h/dwelling period: 2 h/concentration: dextrose 2.5%/inflow: 1.8 L.
During the first year, PTH levels were between 247 and 430 pg/mL while using calcimimetics. After 2 years of starting dialysis, her PTH levels fell below 200 pg/mL, prompting the withdrawal of the calcimimetic. After 6 months of discontinuation, she developed painful and persistent swelling of the small joints, encompassing multiple fingers, hands, and feet. At the same time, she had a high calcium–phosphorus product and severe hyperphosphemia despite high doses of calcium chelators. Hospitalisation was decided for a diagnostic workup, which revealed serum calcium of 8.1 mg/dL, phosphorus 8.5 mg/dL, alkaline phosphatase 65 UI/L, 25-hydroxyvitamin D 13.7 ng/mL, C-reactive protein 7 mg/dL, and PTH 47 pg/mL. Radiographs demonstrated amorphous and multilobulated periarticular calcifications in the proximal phalanges, metacarpals, and metatarsals (Figure 1).
Figure 1. Extraosseous calcifications (amorphous and multilobulated periarticular calcifications) at baseline and 3 months after treatment. (A) and (C) show the photograph of extraosseous calcifications in fingers and hands and the X-ray at baseline, respectively. (B) and (D) show the photograph of both hands and the X-ray without extraosseous calcifications, 3 months after the start of treatment.
We initiated immediate therapeutic interventions, switching the patient to conventional high-flow haemodialysis, prescribed three times a week, 5-h sessions, and pharmacological management: cinacalcet was withheld, calcitriol was discontinued, phosphorus chelator was changed from calcium acetate to sevelamer carbonate, and finally, STS 25 g was administered intravenously after each haemodialysis session. Furthermore, we performed a bone biopsy from the anterior superior iliac crest, following the technique described by Barreto et al. (11), preceded by a pre-labelling procedure (12). Histomorphometry analysis confirmed ABD, with the following parameters: bone formation rate (BFR/BS) 0.0004 mm3/mm2/day, osteoid volume (OV/BV) at 1%, and bone marrow fibrosis (FB) 0%.
The patient showed adequate treatment tolerance, with the calcifications disappearing after a 3-month period of full therapy (Figure 1), and although phosphorus levels were not controlled, the other parameters were in adequate values, such as serum calcium of 9.4 mg/dL, phosphorus 8.5 mg/dL, alkaline phosphatase 85 UI/L, and PTH 111 pg/mL.
After 9 months of STS therapy, she was transferred to a dialysis centre near her home, where session time was reduced to 4 h, achieving better control of calcium and phosphorus (Table 1). Subsequently, the patient continued under a close follow-up in our outpatient clinic, remaining free of new lesions 1 year after STS was suspended, reaching adequate management of calcium and phosphorus although the PTH level was above the standard goal, requiring calcimimetics to be restarted, 1 year after the initial diagnosis (Table 1).
Table 1. Mineral metabolism parameters and treatment during follow-up.
Discussion
We present the case of a young patient after 2 years on PD with low turnover bone disease, complicated by extraosseous calcification. After describing the clinical presentation, we list the available therapeutic strategies to achieve progressive regression of the lesions.
It was essential to consider the possible differential diagnoses for this type of periosteal lesions, since they could be confused with metastatic cancer, bone cysts, and osteosarcoma. Although histologic confirmation is unavailable, findings such as serum PTH, calcium, and phosphorus levels, in a CKD patient context, play a fundamental role in diagnostic certainty. A complete evaluation of medical history, biochemical, and radiographic findings may be sufficient to achieve a correct diagnosis and guide appropriate treatment management.
Pathophysiology of calcification
It is well known that extraosseous calcifications are a rare complication of CKD–MBD and are usually more common in poor and developing countries associated with the massive use of calcium-based phosphate binders and calcium-rich dialysis concentrates. It starts primarily with the supersaturation of plasmatic calcium and phosphorus. In addition, PD may exacerbate this pathologic mechanism, as these patients tend to have positive phosphorus balance unless they are severely malnourished (13).
Furthermore, it is well known that the primary means to improve phosphate transfer across the peritoneal membrane is almost exclusively diffusive process, needing to increase the number of daily peritoneal dialysis cycles and the dwell time of the dialysis solution (14). The use of calcium phosphate binders represents another risk factor because it can induce positive calcium balance that could lead to PTH over-suppression, favouring the development of ABD (13, 15).
In the present case, it was clear that CKD-MBD initially presented with PTH levels within the expected range, even with the use of calcimimetics. However, later during follow-up, it was shown that PTH over-suppression failed to recover despite more than 6 months after discontinuation of cinacalcet, resulting in a biochemical pattern of low bone turnover confirmed on biopsy.
Role of dialysis prescription and phosphate binders
Although the mechanisms underlying the development of ABD are complex, there are two important aspects that should be emphasised. First, overtreatment of secondary hyperparathyroidism without appropriate follow-up could be a key factor contributing to the increase in ABD diagnoses. Second, there is likely a genuine need to redefine the PTH target values. In line with this concept, low bone turnover should be considered when the PTH level is below 150 pg/mL in patients with advanced CKD, with a sensitivity and specificity for diagnosis of 68.6% and 61.2%, respectively (16, 17). However, the target PTH range proposed for CKD patients on dialysis (6) is not a guarantee of normal bone turnover, as illustrated by our case. Pereira et al. analysed 49 patients with CKD on peritoneal dialysis who underwent bone biopsy and found ABD to be a common pattern (42.9%) in patients with PTH within the guideline-recommended plasmatic range (6). Overall, ABD was found in 59% of cases, with a median PTH of 312 (60–631) pg/mL in patients with adynamic bone (7).
Moreover, identifying the underlying causes of low bone turnover is a decisive step in guiding therapeutic strategies, as ABD management is usually multitargeted. This includes a change of dialysis therapy with better control of hypercalcemia and hyperphosphatemia, using calcium-free phosphate binders, and maintaining neutral calcium balance with no net flux of calcium from the bones to the extracellular fluid. Theoretically, with a dialysate calcium concentration of 2.5 mEq/L, net flow of calcium should not occur (18). Although the 2007 CKD–MBD guidelines suggest the use of a calcium concentration in the dialysate between 2.5 and 3.0 mEq/L, a recent kinetic modelling study in haemodialysis patients (19) depicted that a dialysate calcium concentration less than 2.5 mEq/L would be necessary to prevent long-term calcium accumulation in a significant proportion of patients, allowing a small amount of calcium to be removed during ultrafiltration.
Regarding the effect of calcium in the dialysate on bone turnover, it is well known that patients treated with a dialysate calcium concentration of 2.5 mEq/L show changes in parameters, indicative of higher bone turnover. This is likely due to prevention of positive calcium balance and sustained stimulation of PTH secretion, thereby helping to prevent low turnover (20, 21).
In addition, the use of sevelamer has been extensively studied, achieving better control of phosphemia without concomitant use of elemental calcium, eliminating the risk of additional calcium absorption. Furthermore, experimental studies in murine models using sevelamer have shown that apart from normalising serum phosphorus, surprisingly, sevelamer can reverse CKD-induced trabecular osteopenia, increasing osteoblast surfaces in the metaphyseal trabeculae of the tibia and femur, and reinforcing osteoid surfaces, demonstrating remarkably higher bone formation rates (22). Subsequently, Ferreira et al. compared patients who underwent bone biopsies at the beginning and end of a 1-year-period while receiving sevelamer hydrochloride or calcium carbonate. No statistically significant differences in bone turnover or mineralisation were observed between the groups; however, bone formation rate was higher and trabecular architecture improved only in the sevelamer group (23, 24).
Sodium thiosulphate therapy
STS is a well-known drug, with limited but growing evidence, especially from the last decade, mostly in calciphylaxis management (25). Despite several mechanisms proposed, involving complexation with calcium ions and dissolution of calcium deposits, these were recently challenged by O’Neill and Hardcastle (26), who proposed a more relevant antioxidant action that targets inflammation and intimal hyperplasia based on the ability of thiosulphate to be oxidised to sulphate.
Additionally, thiosulphate can be generated in tissues from the mitochondrial sulphide oxidation pathway, being a stable, nontoxic metabolite, and could alter the activity of proteins from many cellular signalling pathways involved in apoptosis, angiogenesis, inflammation, metabolism, proliferation, and oxygen sensing. It can also play a detoxifying role during oxidative stress by increasing the development of glutathione (27).
Moreover, only a few case reports have demonstrated the efficacy of STS in the treatment of extraosseous calcification (28–31). Although there is no strong evidence, STS prescription remains dependent on availability, tolerance, and safety. Its effects appear to achieve partial regression, possibly due to low STS doses at the beginning of therapy, in an effort to avoid adverse reactions.
Our patient was started on full dose, and continued without interruptions, as it was well tolerated. X-ray images promptly demonstrated a substantial reduction in the size of extraosseous calcifications, accompanied by a significant symptomatic improvement. We believe that this more aggressive therapeutic approach facilitated faster lesion regression, needing only a shorter period of treatment for near-complete resolution, without residual lesions after more than 1 year of follow-up after treatment was discontinued.
Finally, it is important to emphasise that CKD–MBD patterns change over time, and the incidence of ABD is increasing, making it necessary, in our opinion, to redefine PTH cutoff points, mainly in PD patients. Likewise, close monitoring of biochemical parameters that guide variations in turnover is necessary to prevent potential risk factors related to low bone turnover, such as age, uraemia, calcium overload, excessive PTH suppression resulting from vitamin D receptor activators, PD itself, and diabetes mellitus.
Key take-away lessons include the importance of early detection and a combined therapeutic approach. Strategies such as the use of non-calcium chelating agents, the change of dialysis therapy or adjustment of dialysis prescription, and the use sodium thiosulphate, represent the most effective means to achieve better outcomes.
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by Complejo Asistencial Victor Rios Ruiz. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
MH: Writing – original draft, Conceptualization, Formal analysis, Investigation, Validation. DE: Conceptualization, Data curation, Formal analysis, Investigation, Validation, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk. for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. (2008) 52:519–30. doi: 10.1053/j.ajkd.2008.03.020
2. Slinin Y, Foley RN, and Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in haemodialysis patients: the USRDS waves 1, 3, and 4 study. JASN. (2005) 16:1788–93. doi: 10.1681/ASN.2004040275
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, and Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance haemodialysis. J Am Soc Nephrol. (2004) 15:2208–18. doi: 10.1097/01.ASN.0000133041.27682.A2
4. Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Fukuhara S, et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in haemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int. (2007) 11:340–8. doi: 10.1111/j.1542-4758.2007.00190.x
5. Ying L, Wen-Chin L, Ben-Chung C, Li LC, Lee CH, Chang WX, et al. Association between the achievement of target range CKD-MBD markers and mortality in prevalent haemodialysis patients in Taiwan by using the kidney disease: improving global outcomes clinical guidelines. BioMed Res Int. (2016) 1523124. doi: 10.1155/2016/1523124
6. KDIGO 2017. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD)Kidney international supplements. Kidney international. (2017) 7:1–59. doi: 10.1016/j.kisu.2017.04.001
7. Pereira L, Magalhaes J, Mendonça L, Neto R, Santos J, Carvalho CG, et al. Evaluation of renal osteodystrophy and serum bone-related biomarkers in a peritoneal dialysis population. J Bone Miner Res. (2022) 37:1689–99. doi: 10.1002/jbmr.4636
8. Cozzolino M, Gallieni M, Chiarelli G, and Brancaccio D. Calcium and phosphate handling in peritoneal dialysis. Contrib Nephrol. Basel Karger. (2006) 150:214–225. doi: 10.1159/000093597
9. Cozzolinoa M, Stucchia A, Rizzoa MA, Brenna I, Elli F, Ciceri P, et al. Phosphate control in peritoneal dialysis. Contrib Nephrol. Basel Karger. (2012) 178:116–23. doi: 10.1159/000337831
10. Pereira L, Mendonc L, Magalhães J, Neto R, Quelhas-Santos J, Oliveira A, et al. Vascular calcification in peritoneal dialysis patients and its association with bone-derived molecules and bone Histomorphometry. Nefrologia. (2024) 44:224–32. doi: 10.1016/j.nefroe.2023.05.003
11. Barreto F, Costa C, Reis L, and Custódio MR. Bone biopsy in nephrology practice. J Bras Nefrol. (2018) 40:366–74. doi: 10.1590/2175-8239-jbn-2017-0012
12. Fusaro M, Re Sartò GV, Gallieni M, Cosmai L, Messa P, Rossini M, et al. Time for revival of bone biopsy with histomorphometric analysis in chronic kidney disease (CKD):Moving from skepticism to pragmatism. Nutrients. (2022) 14:1742. doi: 10.3390/nu14091742
13. Ronco C, Rosner MH, and Crepaldi. Phosphate control in peritoneal dialysis. Contrib nephrol. Basel Karger. (2012) 178:116–23.
14. Botelho C, Rodrigues A, and Santos O. Phosphate removal in peritoneal dialysis regimens: an underestimated adequacy parameter. NDT Plus. (2010) 33:477–8. doi: 10.5301/jn.5000109
15. Schmitt CP, Schaefer F, Huber D, Zahn I, Veldhuis JD, Ritz E, et al. 1,25(OH)2- vitamin D3 reduces spontaneous and hypocalcemia- stimulated pulsatile component of parathyroid hormone secretion. J Am Soc Nephrol. (1998) 9:54–62. doi: 10.1681/ASN.V9154
16. Nagy E, Sobh M, Abdalbary M, Elnagar S, Elrefaey R, Shabaka S, et al. Is adynamic bone always a disease? Lessons from patients with chronic kidney disease. J Clin Med. (2022) 11:7130. doi: 10.3390/jcm11237130
17. Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. (2016) 67:559–66. doi: 10.1053/j.ajkd.2015.06.023
18. Wang AY. Calcium balance and negative impact of calcium load in peritoneal dialysis patients. Perit Dial Int. (2014) 34:345–52. doi: 10.3747/pdi.2013.00177
19. Gotch FA, Kotanko P, Thijssen S, and Levin NW. The KDIGO guideline for dialysate calcium will result in an increased incidence of calcium accumulation in hemodialysis patients. Kidney Int. (2010) 78:343–50. doi: 10.1038/ki.2010.157
20. Spasovski G, Gelev S, Masin-Spasovska J, Selim G, Sikole A, and Vanholder R. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone. (2007) 40:698–703. doi: 10.1016/j.bone.2007.06.014
21. Sethi S, Dhooria HS, and Goyal S. Study on the effect of low calcium dialysate on biochemical profile of adynamic bone disease in patients on maintenance hemodialysis. Saudi J Kidney Dis Transpl. (2023) 34:224–34. doi: 10.4103/1319-2442.393995
22. Mathew S, Lund R, Strebeck F, Tustison KS, Geurs T, and Hruska KA. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrology. (2007) 18:122–30. doi: 10.1681/ASN.2006050490
23. Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. (2008) 19:405–12. doi: 10.1681/ASN.2006101089
24. Frazao J and Adragao T. Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. Kidney Int. (2008) 74:S38–43. doi: 10.1038/ki.2008.544
25. Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, and Lacson E Jr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. (2013) 8:1162–70. doi: 10.2215/CJN.09880912
26. O’Neill WC and Hardcastle KI. The chemistry of thiosulfate and vascular calcification. Nephrol Dial Transplant. (2012) 27:5216. doi: 10.1093/ndt/gfr375
27. Zhang M, Dugbartey G, Juriasingani S, and Sener A. Hydrogen sulfide metabolite, sodium thiosulfate: clinical applications and underlying molecular mechanisms. Int J Mol Sci. (2021) 22:6452. doi: 10.3390/ijms22126452
28. Malbos S, Urena-Torres P, Cohen-Solal M, Trout H, Lioté F, Bardin T, et al. Sodium thiosulphate treatment of uraemic tumoral calcinosis. Rheumatology. (2014) 53:547–51. doi: 10.1093/rheumatology/ket388
29. Yatzidis H and Agroyannis B. Sodium thiosulfate treatment of soft-tissue calcifications in patients with end-stage renal disease. Perit Dial Bull. (1987) 7:2502. doi: 10.1177/089686088700700411
30. Kyriakopoulos G and Kontogianni K. Sodium thiosulfate treatment of tumoral calcinosis in patients with end-stage renal disease. Ren Fail. (1990) 12:2139. doi: 10.3109/08860229009060727
Keywords: low bone turnover, extraosseous calcifications, sodium thiosulphate, adynamic bone disease, peritoneal dialysis
Citation: Hernandez-Pérez M and Enos D (2026) Evanescent extraosseous calcifications in low turnover bone: management and outcomes: a case report. Front. Nephrol. 5:1702475. doi: 10.3389/fneph.2025.1702475
Received: 10 September 2025; Accepted: 22 December 2025; Revised: 25 November 2025;
Published: 14 January 2026.
Edited by:
Md. Mohaimenul Islam, University at Buffalo, United StatesReviewed by:
Vijay Chander Bukka, Nizam’s Institute of Medical Sciences, IndiaJunhao Chen, The Second Affiliated Hospital of Kunming Medical University, China
Petru Adrian Radu, Nephrology Clinical Hospital “Dr. Carol Davila”, Romania
Julia Vaz, University of São Paulo, Brazil
Copyright © 2026 Hernandez-Pérez and Enos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mariel Hernandez-Pérez, bWFyaWpocEBob3RtYWlsLmNvbQ==
†ORCID: Mariel Hernandez-Pérez, orcid.org/0000-0002-0329-8733
Daniel Enos, orcid.org/0000-0001-9734-2493